After Lixi: What Zealand Is Doing Next

Zealand CEO Britt Meelby Jensen says the Danish developer of novel peptides for treating gastrointestinal and metabolic diseases is successfully raising its global profile via a growing proprietary pipeline.

Magnify
Zealand's CEO Seeks To Focus Attention On Its Proprietary Pipeline • Source: Shutterstock

Denmark-basedZealand Pharma AS says its profile among international investors has benefited hugely since its shares were listed on the US Nasdaq last August, giving it exposure to highlight a promising late-stage proprietary pipeline and ongoing collaborations with Sanofi and Boehringer Ingelheim GMBH.

Hitherto largely known for developing the Sanofi-partnered GLP-1 receptor agonist Lyxumia (lixisenatide), the Danish biotech has under its CEO Britt...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By 

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By 

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By 

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

More from Business